April 2024 in “Journal of clinical medicine” This review discusses various therapeutic options for frontal fibrosing alopecia and highlights the need for more research, as existing data are largely retrospective and lack precise treatment guidelines.
1 citations
,
January 2024 in “Dermatologic Therapy” This study found that both methotrexate and azathioprine were equally effective and well-tolerated in improving symptoms of lichen planopilaris over six months, with no significant difference between the two treatments in terms of efficacy.
November 2023 in “Journal of Cosmetic Dermatology” This study concluded that while both 5% topical and 1 mg oral minoxidil significantly improved hair diameter in androgenetic alopecia patients, there was no significant difference in overall effectiveness or patient satisfaction between the treatments.
July 2023 in “Dermatology Practical & Conceptual” This study found that a positive anagen pull test can be an indicator of lichen planopilaris activity, suggesting its utility in the clinical assessment of this condition.
January 2023 in “Dermatologic Therapy” This review found that intralesional corticosteroid injections and 5-alpha-reductase inhibitors were reported as the most effective treatments for frontal fibrosing alopecia, with oral isotretinoin showing promise for facial papule improvement.
August 2022 in “Journal of The European Academy of Dermatology and Venereology” 4 citations
,
January 2022 in “Dermatology Research and Practice” In this study, methotrexate therapy with or without corticosteroids showed similar efficacy and safety in treating patients with lichen planopilaris, with no significant differences in the primary outcome or adverse effects between the two groups.
January 2022 in “Indian journal of drugs in dermatology” This review of available data noted that oral minoxidil shows promise for treating various alopecia disorders, including androgenetic alopecia and alopecia areata, but high-quality studies are needed to better understand its effectiveness and mechanisms in these conditions.
2 citations
,
January 2022 in “Skin appendage disorders” This study found that for people with androgenetic alopecia, increasing the dosage of low-dose oral minoxidil is associated with improvements in hair diameter and density, but also raises the risk of hypertrichosis and cardiovascular adverse events.
16 citations
,
June 2021 in “Journal of Dermatological Treatment” This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.
21 citations
,
March 2021 This study reviewed the literature on low-dose oral minoxidil as a primary treatment for various hair loss disorders, concluding that it is a successful and well-tolerated alternative to topical minoxidil for patients with poor adherence to other therapies.
8 citations
,
December 2020 in “Skin appendage disorders” This study observed eyebrow regrowth in 7 patients with frontal fibrosing alopecia treated with low-dose oral minoxidil, suggesting it may be a promising treatment option, especially in early disease stages.
9 citations
,
October 2020 in “Journal of The American Academy of Dermatology” This letter discusses the limited adaptation of low dose oral minoxidil for androgenetic alopecia in North America and reports no new clinical results; the authors suggest safety concerns or unclear dosing may be factors.
14 citations
,
August 2020 in “Dermatologic Therapy” This study reported that low-dose oral minoxidil is generally safe for treating various types of hair loss, though it may cause hypertrichosis and pedal edema, especially at higher doses.
59 citations
,
July 2020 in “Journal of The American Academy of Dermatology” This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.
19 citations
,
June 2020 in “International Journal of Dermatology” In this systematic review, oral minoxidil was found to be a safe and effective treatment for androgenetic alopecia and alopecia areata, with additional benefits for female pattern hair loss and other types of alopecia, although common side effects included hypertrichosis and postural hypotension.
19 citations
,
May 2020 in “Journal of The American Academy of Dermatology” This case series reports the experience of using oral minoxidil at 1.25 mg/day in 32 patients with male androgenetic alopecia, noting both therapeutic effects and potential adverse reactions.
15 citations
,
April 2020 in “Journal of The American Academy of Dermatology” This article discusses the challenges of treating lichen planopilaris, reviews various therapeutic options including minoxidil, and reports no new clinical findings.
14 citations
,
April 2019 in “International Journal of Women's Health” This review highlights current treatment options for frontal fibrosing alopecia, noting that 5-α-reductase inhibitors, intralesional steroids, and hydroxychloroquine have the highest evidence of effectiveness, while other therapies show variable results and need further research.
32 citations
,
January 2019 in “American Journal of Clinical Dermatology” This review discusses the use of topical minoxidil for various types of alopecia and reports mixed evidence on its efficacy, with stronger support noted for conditions like eyebrow hypotrichosis and chemotherapy-induced alopecia.
48 citations
,
November 2018 in “Journal of dermatological treatment” In a study reviewing 291 patients with lichen planopilaris, findings revealed that women were more commonly affected than men, cyclosporine and methotrexate were most effective in achieving remission, and 5-alpha reductase inhibitors and systemic retinoids were particularly beneficial for frontal fibrosing alopecia.
36 citations
,
September 2018 in “Dermatologic Therapy” This study found that 78% of patients continued taking oral minoxidil for androgenetic or traction alopecia, with 33% reporting decreased hair shedding and 28% noting increased scalp hair.
19 citations
,
July 2017 in “Clinical and experimental dermatology” This study provides one of the first descriptions of the demographic, clinical, and therapeutic characteristics of lichen planopilaris in Chilean adults, reporting that treatment usually reduced or halted disease progression.
22 citations
,
January 2017 in “Skin appendage disorders” This research analyzed 72 primary scarring alopecia cases in a Barcelona hospital, finding that the majority involved women, with a lymphocytic infiltrate and subacute onset in many cases, leading to stable disease, while neutrophilic cases had more acute episodes.
27 citations
,
July 2013 in “Journal of Dermatological Science” The conclusion is that androgenetic alopecia and senescent alopecia have unique gene changes, suggesting different causes and potential treatments for these hair loss types.
160 citations
,
March 2009 in “Seminars in Cutaneous Medicine and Surgery” This article reviews lichen planopilaris, its presentation, and treatment challenges, and emphasizes the need for more research into its pathogenesis and therapy efficacy; it reports no new findings.
